Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT03003052
Recruiting Observational

Assessing Current Clinical Concepts in Dental Practice

NCT03003052 · tracked via the Priya Life Science UK tracker
Sponsor
The Campbell Clinic, UK
Phase
Observational
Started
2017-01
Last updated
2026-10-20

Condition(s) studied

Dental Implant

Investigational drug(s) / intervention(s)

Dental implants

Dental implants: Data collection from pre-implant assessment, implant surgery, and hygiene recall appointments, to assess implant survival and success.

Study summary

This purpose of this database is to collect, store and use appropriately derived data from routine patient care in a specialist dental practice. Comprehensive observational data will be gathered, systematically organised and be continuously updated. This data will be used to evaluate treatment outcomes and identify areas for improvement. This will contribute to the existing evidence base to validate new and current clinical concepts in dentistry. Patient consent will be sought for this, and all data extracted from patient notes will be stored and used anonymously. Use of the Oral Health Impact Profile (OHIP) -14 questionnaire pre and post treatment will be used to assess patient satisfaction with outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. be a patient at The Campbell Clinic 2. be planning to undergo or have undergone specialist dental treatment, usually involved dental implants 3. be able to read and understand Patient Information Sheet 4. Have signed informed consent form Exclusion Criteria: 1. concern that patient has not understood patient information sheet (e.g. due to language /interpretation issues) 2. not willing to sign consent form 3. any medical condition/medication that might compromise implant success

Primary outcome measure(s)

  • Implant Success - clinical measures — up to 4 years
    Assessment of implant success (signs of implant mucositis peri-implantitis), functionality and aesthetic results. Categorised/grouped by surgery type: single/multiple implant, use of sinus lift, and other variables.

Trial sites (1)

FacilityCityRegionStatus
The Campbell Clinic Nottingham United Kingdom Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03003052 on ClinicalTrials.gov ↗ ← All trials in the UK